

Meta-analysis supports elective revascularization and medical therapy for reducing cardiac death

18 May 2021

The ISCHEMIA trial found no significant difference between an invasive vs. a conservative strategy in patients with chronic coronary syndromes and moderate to severe ischemia at a mean of 3.2 years. However, the cumulative difference in the estimates of cardiac death between the invasive and conservative strategies tended to increase numerically over time (e.g., 0.3% in favor of the invasive strategy at two years and 1.3% at five years). Because the ISCHEMIA trial was not powered for cardiac mortality and did not focus on long-term follow-up, the rationale for a meta-analysis emerged.

At EuroPCR 2021, Navarese and colleagues present the results of a new meta-analysis of revascularization plus [medical therapy](#) versus medical therapy alone. A total of 19,806 patients with chronic coronary syndromes undergoing elective revascularization from 25 randomised [trials](#) were pooled, and outcomes were extracted at the longest available follow-up. The primary endpoint was cardiac [death](#). Secondary endpoints were all-cause death, spontaneous myocardial infarction, any myocardial infarction and stroke.

The authors found a statistically significant 21% relative risk reduction in cardiac death with revascularization plus medical therapy (risk ratio 0.79, 95% confidence interval 0.67 to 0.93, p

APA citation: Meta-analysis supports elective revascularization and medical therapy for reducing cardiac death (2021, May 18) retrieved 4 June 2022 from <https://medicalxpress.com/news/2021-05-meta-analysis-elective-revascularization-medical-therapy.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.